Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted ‘Breakthrough Device Designation’ for its blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Last year, the Company’s early-stage breast cancer detection test…
eTurboNews amanqaku ngababhalisi kuphela. Umrhumo ngu fREE.
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
Ababhalisi bangena apha Cofa apha ukuze ubhalise FREE
INTO ONOKUYITHATHA KWELI NQAKU:
- This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA.
- Last year, the Company’s early-stage breast cancer detection test….
- For its blood test to detect early-stage prostate cancer.
